Drug intelligence / Profile preview

Sym029

Development stage: Discontinued
Lead developer: Symphogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**Sym029** is a human IgG monoclonal antibody that acts as an agonist targeting **CD40** (TNFRSF5), a member of the TNF receptor superfamily expressed on antigen-presenting cells such as dendritic cells. Developed by **Symphogen A/S**, it stimulates dendritic cells to enhance anti-tumor immune responses, positioning it as an investigational immunotherapy for cancer. Preclinical studies support its use in oncology research, though clinical development has been discontinued.

Other names: Sym-029Sym029Sym 029

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on Sym029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sym029.

Explore the full profile